Total de visites

Visites
VHIO ...711

Total de visites per mes

d’octubre 2023de novembre 2023de desembre 2023de gener 2024de febrer 2024de març 2024d’abril 2024
VHIO ...25151219272229

Visites per país

Visites
Espanya507
Estats Units60
França25
Suècia19
Irlanda15
Xina7
Costa d'Ivori5
Regne Unit5
Corea del Sud4
Singapur4

Visites per ciutat

Visites
Barcelona263
Capellades60
Sabadell20
Dublin15
Sant Feliu de Llobregat14
Chandler12
L'Hospitalet de Llobregat12
Molins de Rei11
Ashburn9
Terrassa9

Documents més visitats

Visites
Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication291
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial230
LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy221
The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer204
Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights203
New clinical trial designs in the era of Precision Medicine201
Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancer201
Cancer Core Europe: A translational research infrastructure for a European mission on cancer196
Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial194
BRCA2 and Other DDR Genes in Prostate Cancer192